Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

OBJECTIVE The only approved pharmacological approach for the symptomatic treatment of Alzheimer's disease in Japan is the use of a cholinesterase inhibitor, donepezil hydrochloride. Recent in vivo and in vitro studies raise the possibility that cholinesterase inhibitors can slow the progression of Alzheimer's disease. The purpose of the present study was to determine whether donepezil has a neuroprotective effect in Alzheimer's disease by using the rate of hippocampal atrophy as a surrogate marker of disease progression. METHOD In a prospective cohort study, 54 patients with Alzheimer's disease who received donepezil treatment and 93 control patients with Alzheimer's disease who never received anti-Alzheimer drugs underwent magnetic resonance imaging (MRI) twice at a 1-year interval. The annual rate of hippocampal atrophy of each subject was determined by using an MRI-based volumetric technique. Background characteristics, age, sex, disease duration, education, MRI interval, apolipoprotein E (APOE) genotype, and baseline Alzheimer's Disease Assessment Scale score were comparable between the treated and control groups. RESULTS The mean annual rate of hippocampal volume loss among the treated patients (mean=3.82%, SD=2.84%) was significantly smaller than that among the control patients (mean=5.04%, SD=2.54%). Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant. CONCLUSIONS Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  S. Shimohama,et al.  Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. , 1997, Annals of neurology.

[3]  S. Wisniewski,et al.  Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[4]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[5]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[6]  R. Sperling,et al.  Donepezil therapy in clinical practice: a randomized crossover study. , 2000, Archives of neurology.

[7]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[8]  C. Jack,et al.  MRI‐Based Hippocampal Volume Measurements in Epilepsy , 1994, Epilepsia.

[9]  Gregory McCarthy,et al.  Quantitative magnetic resonance imaging in temporal lobe epilepsy: Relationship to neuropathology and neuropsychological function , 1992, Annals of neurology.

[10]  H Matsuda,et al.  Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  E. Mori,et al.  Medial temporal structures relate to memory impairment in Alzheimer’s disease: an MRI volumetric study , 1997, Journal of neurology, neurosurgery, and psychiatry.

[12]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[13]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[14]  A. Kertesz.  Long-term donepezil treatment in patients with Alzheimer’s disease , 2004 .

[15]  M. Farlow,et al.  A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.

[16]  C. Jack,et al.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.

[17]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[18]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[19]  K. Davis,et al.  The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.

[20]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[21]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[22]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[23]  C. Cotman,et al.  Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Wolf,et al.  Muscarinic Regulation of Alzheimer's Disease Amyloid Precursor Protein Secretion and Amyloid β-Protein Production in Human Neuronal NT2N Cells (*) , 1995, The Journal of Biological Chemistry.

[25]  Hiroaki Kazui,et al.  Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele , 2002 .

[26]  H. Wiśniewski,et al.  Pathology of Alzheimer's disease. , 1991, The Psychiatric clinics of North America.

[27]  K. Davis,et al.  Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Nordberg,et al.  Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25‐35) in rat PC12 cells , 1998, Neuroreport.

[29]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[30]  S. Shimohama,et al.  Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity , 1997 .

[31]  S Lehéricy,et al.  Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. , 1994, AJNR. American journal of neuroradiology.

[32]  E. Mori,et al.  Clinical Diagnosis of Dementia with Lewy Bodies in a Japanese Dementia Registry , 1999, Dementia and Geriatric Cognitive Disorders.

[33]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[34]  PhilipR. Wenham,et al.  Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.

[35]  Hiroaki Kazui,et al.  Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer’s disease , 2001, Neurology.

[36]  H. Soininen,et al.  Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[37]  Rachelle S. Doody,et al.  DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .